ABCL - AbCellera Biologics EPS misses by $0.01 beats on revenue

AbCellera Biologics (ABCL): Q1 GAAP EPS of $0.37 misses by $0.01.Revenue of $202.74M (+4260.0% Y/Y) beats by $3.39M.Total programs under contract of 119, up 63% year-over-yearAs of March 31, 2021, the Company had 119 discovery programs (up 63% from 73 on March 31, 2020) that are either completed, in progress, or under contract with 29 partners (up from 24 on March 31, 2020). The Company has started discovery on a cumulative total of 52 of these programs (up from 47 on March 31, 2020).Shares -6.3%.Press Release

For further details see:

AbCellera Biologics EPS misses by $0.01, beats on revenue